pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Anti-inflammatory
drug · small molecule
save

Anti-inflammatory

pre_registrationupdated 7mo ago
by AimMax Therapeutics Inc🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 2
  • companyBrigham and Women's Hospital1 co-mentions · 1 sources
  • tagsiRNA1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 11 investigational indications.

targets

Mitogen-activated protein kinase 11Mitogen-activated protein kinase 14

all catalysts(0)

nothing on the calendar yet

Trials studying Anti-inflammatory

  • N/ALong Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)active not recruitingn=14
  • phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participantscompletedn=138
  • phase2Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.enrolling by invitationn=50
  • N/AEffect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adultsnot yet recruitingn=158
  • N/AAnti-Inflammatory Dietary Intervention for Rheumatoid Arthritisunknownn=32

News(10)

  • As part of sales reorganization, Novo will cut 215 employees at US HQ
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1d ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 2d ago
  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 4d ago
  • STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
    Once again, a hot new technology that was supposed to speed up drug research has fallen flat.
    stat · 13d ago
  • Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor
    Rezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a cardiovascular disease.
    fiercebiotech · 16d ago
  • Sanofi stops development of Nurix-partnered immune drug
    The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
    biopharma_dive · 17d ago
  • AbbVie bets up to $1.47B for Nxera’s discarded IBD program
    AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
    biospace · 17d ago
  • Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
    Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…
    biospace · 17d ago
  • AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
    AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
    fiercebiotech · 17d ago
  • Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
    Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
    biospace · 25d ago
view all news mentions →
MOA
MAP kinase p38 beta inhibitor; MAP kinase p38 alpha inhibitor
indication
Post-Operative Pain
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?